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Background: BDCA-2 is an anti-inflammatory receptor uniquely expressed on plasmacytoid dendritic cells.
Results: Glycan arrays and x-ray structural analysis have been used to define the mechanism of sugar binding to BDCA-2.
Conclusion: BDCA-2 binds selectively to glycans containing the epitope Gal1–3/4GlcNAc1–2Man.
Significance: Binding of BDCA-2 to unusual galactose-terminated glycans on IgG or other serum glycoproteins provides a
potential mechanism for modulating the immune response.
Blood dendritic cell antigen 2 (BDCA-2; also designated
CLEC4C or CD303) is uniquely expressed on plasmacytoid
dendritic cells. Stimulation of BDCA-2 with antibodies leads
to an anti-inflammatory response in these cells, but the nat-
ural ligands for the receptor are not known. The C-type car-
bohydrate recognition domain in the extracellular portion of
BDCA-2 contains a signature motif typical of C-type animal
lectins that bindmannose, glucose, or GlcNAc, yet it has been
reported that BDCA-2 binds selectively to galactose-termi-
nated, biantennary N-linked glycans. A combination of gly-
can array analysis and binding competition studies with
monosaccharides and natural and synthetic oligosaccharides
have been used to define the binding epitope for BDCA-2 as
the trisaccharide Gal1–3/4GlcNAc1–2Man. X-ray crystal-
lography and mutagenesis studies show that mannose is
ligated to the conserved Ca2 in the primary binding site that
is characteristic of C-type carbohydrate recognition domains,
and the GlcNAc and galactose residues make additional
interactions in a wide, shallow groove adjacent to the primary
binding site. As predicted from these studies, BDCA-2 binds
to IgG, which bears galactose-terminated glycans that are not
commonly found attached to other serum glycoproteins.
Thus, BDCA-2 has the potential to serve as a previously
unrecognized immunoglobulin Fc receptor.
Blood dendritic cell antigen 2 (BDCA-2)3 is a defining feature
of human plasmacytoid dendritic cells. It was originally identi-
fied as the target for one of several monoclonal antibodies that
recognize antigens that are uniquely expressed on this unusual
population of circulating leukocytes (1). Plasmacytoid dendritic
cells have properties often associated with classical dendritic
cells, such as the ability to internalize and present antigens, but
they are circulating cells that develop through a distinct lineage
(2, 3). They are believed to play an important role in initial
stages of the adaptive immune response and have therefore
been an important target in vaccine development.
Multiple receptors that mediate internalization of antigens
in antigen-presenting cells are expressed on the surface of clas-
sical dendritic cells. Several of these endocytic receptors, such
as DC-SIGN and the mannose receptor, have sugar binding
activity and containCa2-dependent carbohydrate recognition
domains (C-type CRDs) (4, 5). However, much less is known
about C-type lectins on plasmacytoid dendritic cells. Sequence
analysis reveals that BDCA-2 also contains a C-type CRD,
despite the fact that it falls into a structurally distinct group of
type 2 transmembrane receptors (6, 7). Although the cytoplas-
mic domain of the polypeptide is short and lacks obvious inter-
nalization or signaling motifs, BDCA-2 has a well defined link
to signaling pathways as a result of its associationwith the com-
mon Fc receptor  subunit (8, 9). Stimulation of BDCA-2 with
antibodies initiates anti-inflammatory pathways through asso-
ciation with Syk kinase and adapter proteins such as Btk and
BLNK, leading to stimulation of phospholipase C and a reduc-
tion in secretion of type 1 interferon (1, 10).
Although the sequence of BDCA-2 suggests that it contains a
C-type carbohydrate recognition domain, there is conflicting
evidence about how it might bind such ligands. The primary
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sugar-binding site in a C-type CRD is usually centered on a
conserved bound Ca2 that makes coordination bonds to two
adjacent hydroxyl groups in the pyranose ring of a monosac-
charide residue (4). A group of conserved amino acid side
chains simultaneously ligate to the Ca2 and form hydrogen
bonds with the sugar hydroxyl groups. Some of these amino
acid residues are conserved in all sugar-binding C-type CRDs,
whereas others vary with the type of sugar bound. C-type CRDs
containing glutamic acid and asparagine residues in the
sequence EPN at the primary Ca2 site bind mannose, glucose,
and N-acetylglucosamine through equatorial 3- and 4-OH
groups, whereas in CRDs that bind sugars such as galactose and
N-acetylgalactosamine, in which the 4-OH group is axial, the
corresponding sequence is QPD (11). In keeping with the pres-
ence of the EPNmotif in BDCA-2, it binds to neoglycoproteins
that carrymannose, GlcNAc, and glucose but not to those bear-
ing galactose or N-acetylgalactosamine (12). Therefore, it is
surprising that glycan array analysis indicates that BDCA-2
binds selectively to galactose-terminated biantennary glycans
(13). In addition, a published structure of BDCA-2 reveals a
domain-swapped structure that lacks many elements of the
typical Ca2-dependent binding site (14).
To clarify the apparent contradictions between the known
mechanism of sugar binding to C-type CRDs and the apparent
properties of BDCA-2, the ligand binding properties of the
CRD have been investigated further. Binding, structural, and
mutational analysis of the receptor suggest that it has a primary
binding site for mannose, but that selectivity for galactose-ter-
minated glycans is achieved through a secondary binding site.
The results reconcile the existing data and help to define poten-
tial biological ligands for BDCA-2.
Materials andMethods
Sugars—Methyl glycosides were purchased from Sigma and
Carbosynth. Egg yolk glycopeptide was purified according to
the published protocol (15), except that Sephacryl S-75 and
S-peptide columns (1.5 300mm;GE Life Sciences) were used
for gel filtration.
Biantennary oligosaccharides were prepared by digestion of
the egg yolk glycopeptide (40mol) with peptideN-glycosidase
(7,500 units; New England Biolabs) at 37 °C for 72 h in 100 mM
Tris-Cl, pH 7.8, and was purified by chromatography on an
S-peptide column run in 1% acetic acid followed by passage
over an Oasis C18 column (Waters) pre-equilibrated with 5 ml
of methanol and 5 ml of water. Partial desialylation was
achieved by incubation in 1 ml of 40 mM HCl for 6 h at 37 °C
followed by neutralization with 0.4 ml of 1 M NaHCO3. The
oligosaccharide was purified by two passes over the S-peptide
column run in 2 mM Tris. Separation of charged forms was
performedby chromatographyona1-ml columnofQAE-Seph-
adex (A25 resin from GE Life Sciences) equilibrated in 2 mM
Tris (16). Fully desialylated oligosaccharidewas elutedwith 6
1 ml of 2 mM Tris, monosialylated oligosaccharide was eluted
with 6  1 ml of 2 mM Tris containing 20 mM NaCl, and the
remaining disialylated oligosaccharidewas elutedwith 6 1ml
of 2 mM Tris containing 70 mMNaCl. Eluted pools were lyoph-
ilized and desalted on the S-peptide column run in 1% acetic
acid. The separated oligosaccharides were quantified by
anthrone assay and characterized by NMR and mass
spectrometry.
The disaccharide GlcNAc1–2Man, purchased from Dex-
tra, was extended by incubation of 25 mol in 2 ml of 50 mM
Tris-Cl, pH7.4, containing 20mMMgCl2with 35mol ofUDP-
galactose (Sigma), 100 milliunits of galactosyltransferase from
bovine milk (Sigma), and 20 milliunits of alkaline phosphatase
(Sigma) for 4 h at 37 °C. The reaction was lyophilized, dissolved
in 4 ml of chromatography solvent A (n-butanol:acetic acid:
H2O, 3/1/1), and fractionated on a 5-ml column of silica gel.
The trisaccharide product eluted between 18 and 30 ml, as
determined by chromatography of aliquots on high perfor-
mance thin layer silica plates that were run in solvent A and
stained with orcinol. The product was further purified by gel
filtration on a 15  300-mm S-peptide column run in water.
The final product was quantified by anthrone assay and char-
acterized by NMR and mass spectrometry (supplemental Figs.
S1 and S2).
Affinity Resins—Mannose-Sepharose was prepared by the
divinyl sulfone coupling method (17). Glycopeptide (25 mg),
partially desialylated by heating at 70 °C for 30 min in 50 mM
HCl and purified by gel filtration on a 15-ml Sephadex G-25
column run in 1% acetic acid, was coupled toAffi-Gel 10 (10ml)
in 6 ml of 0.1 M sodium HEPES buffer, pH 7.5, for 3 h at 4 °C.
Expression Plasmids—A cDNA for BDCA-2 was amplified
from a human testis cDNA library (Clontech/Takara) by PCR
(Advantage 2 polymerasemix; Takara), cloned into the pCR2.1-
TOPO vector (Invitrogen), and sequenced using an Applied
Biosystems 310 genetic analyzer. The portion of the cDNA
encoding the CRD was reamplified with forward primers
designed to provide an initiation sequence in the pT5T expres-
sion vector (18). In addition to the natural termination codon, a
version with nucleotides encoding the biotinylation sequence
Gly-Leu-Asn-Asp-Ile-Phe-Glu-Ala-Gln-Lys-Ile-Glu-Trp-His-
Glu (19) at the 3 end was created using an alternative reverse
primer. Mutagenesis was performed by two-step PCR (20)
using the original cDNA clone as template. Expressionwas per-
formed in Escherichia coli strain BL21(DE3), which was co-
transformed with pBirA plasmid encoding biotin ligase (19) for
expression of biotin-tagged proteins.
Protein Purification and Analysis—Expression of the wild
type CRD from human BDCA-2 following published protocols
for other C-type CRDs resulted in inclusion bodies that were
isolated as described (21). Inclusion bodies from 2 liters of bac-
terial culture were dissolved in 30 ml of 6 M guanidine HCl
containing 100 mM Tris-Cl (pH 7.8) and incubated in the pres-
ence of 0.01% (v/v) 2-mercaptoethanol for 30 min at 4 °C. Fol-
lowing centrifugation for 30 min at 100,000  g in a Beckman
Ti70.1 rotor, the supernatant was diluted dropwise into 120 ml
of 0.5 M NaCl, 25 mM Tris-Cl, pH 7.8, and 25 mM CaCl2 at 4 °C,
followed by dialysis against 2 changes of 2 liters of the same
buffer. Insolublematerial was removed by centrifugation for 30
min at 50,000 g in a Beckman JA20 rotor, and the supernatant
was applied to a 5-ml column of glycopeptide-agarose. After
rinsing with 12 ml of 150 mMNaCl, 25 mM Tris-Cl, pH 7.8, and
25 mM CaCl2, the bound protein was eluted with 10  1-ml
aliquots of 150 mM NaCl, 25 mM Tris-Cl, pH 7.8, and 2.5 mM
EDTA. Fractions containing the CRD were identified by ana-
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lyzing aliquots on SDS-polyacrylamide gels, with protein
detected by staining with Coomassie Blue.
Mutant forms of the CRD were expressed in the same way,
but following initial dialysis against the renaturation buffer, the
proteins from 4–6 liters of culture were further dialyzed
against two changes of 2 liters of H2O and lyophilized. The
lyophilized proteins were taken up in 6 ml of 150 mM NaCl, 25
mM Tris-Cl, pH 7.8, and 25 mM CaCl2 and centrifuged at
100,000  g in a Beckman TLA100.4 rotor for 30 min at 4 °C.
The supernatant was applied to a 10-ml column of mannose-
Sepharose, which was washed five times with 2-ml aliquots of
150 mM NaCl, 25 mM Tris-Cl, pH 7.8, and 25 mM CaCl2 and
elutedwith three 2-ml aliquots and eight 1-ml aliquots of 50mM
NaCl, 25 mM Tris-Cl, pH 7.8, and 2.5 mM EDTA.
Gel filtration was performed on a 1  30-cm Superdex 200
column (GE Healthcare) eluted with 10 mM Tris-Cl (pH 7.8),
100 mM NaCl, and 2.5 mM EDTA at a flow rate of 0.5 ml/min,
with absorbancemonitored at 280 nm. Gel electrophoresis was
performed on SDS-polyacrylamide gels containing 17.5% (w/v)
acrylamide.
Glycan Binding Assays—Biotinylated protein was incubated
overnight with Alexa 488-labeled streptavidin (Invitrogen) at a
ratio of 2 mol of CRD to 1 mol of streptavidin subunit. The
mixture was applied to a 1-ml column of mannose-Sepharose,
which was washed with loading buffer, and the complex was
eluted with 0.5-ml aliquots of elution buffer. The protein was
tested against version 5.1 of the glycan array of the Consortium
for Functional Glycomics using the standard protocol.
Competition binding assays were performed as previously
described for mincle (22). 125I-Man-BSA and 125I-IgG reporter
ligands were prepared by radioiodination (23) of Man31-BSA
(E-Y Laboratories) and human IgG (Sigma).
Crystallization, Data Collection, and Structure Deter-
mination—Crystals of human BDCA-2 complexed with
-methyl mannoside were grown by hanging drop vapor diffu-
sion at 22 °C using amixture of 0.13:0.13l of protein:reservoir
solution in the drop, with the protein solution comprising 5
mg/ml CRD fromBDCA-2, 5mMCaCl2, 10mMTris-Cl, pH 8.0,
25 mM NaCl, and 50 mM -methyl mannoside. The reservoir
solution contained 0.2 M MgCl2 and 20% polyethylene glycol
3.35 K. Crystals were dipped in a freezing solution containing
30% polyethylene glycol 3.35 K, 0.2 M MgCl2, 5 mM CaCl2, 10
mMTris, pH 8.0, 25mMNaCl, and 50mM-methylmannoside,
before being frozen in liquid nitrogen for data collection. Dif-
fraction data were measured at 100 K on Beamline 23-ID-D at
the Advanced Photon Source of Argonne National Laboratory.
Crystals of human BDCA-2 complexed with Gal1-
4GlcNAc1–2Man were grown using a mixture of 0.2:0.1 l of
protein:reservoir solution, at 22 °C, from a protein solution
comprising 6.2 mg/ml BDCA-2, 5 mM CaCl2, 10 mM Tris-Cl,
pH 8.0, 25 mM NaCl, and 20 mM Gal1–4GlcNAc1-
2Man. The reservoir solution contained 0.2 NH4Cl and 20%
polyethylene glycol 3.35 K. Crystals were dipped in oil (Lan-
caster PFO-XR75) before being frozen in liquid nitrogen for
data collection. Diffraction data were measured at 100 K on
Beamline 12-2 at Stanford Synchrotron Radiation Laboratory.
All diffraction data were integrated with XDS (24) and scaled
with AIMLESS (25). The statistics are summarized in Table 1.
The high resolution structure of BDCA-2 complexed with
-methyl mannoside was solved by molecular replacement,
using the program Phaser (26). The model used for molecular
replacement was prepared from the coordinates for the CRD of
cow mincle (Protein Data Bank entry 4ZRV), with three Ca2
molecules and no carbohydrate orwatermolecules. Themolec-
ular replacement solution confirmed that the space group was
P22121, with two monomers in the asymmetric unit. The lower
resolution structure of BDCA-2 complexed with Gal1-
4GlcNAc1–2Man was solved using the partially refined high
resolution structure of BDCA-2 complexed with -methyl
mannoside. Difference Fourier maps clearly showed Gal1-
4GlcNAc1–2Man in both monomers. Model building and
refinement were performed with Coot (27) and PHENIX (28).
Refinement included individual positional and isotropic tem-
perature factor refinement and occupancy refinement for resi-
dues with alternate conformations. Refinement statistics are
shown in Table 2.
Results
Expression of the CRD from BDCA-2—Comparison of both
the overall structural organization of BDCA-2 and the
sequence of the carbohydrate recognition domain place it in a
subgroup of the family of type II transmembrane receptors that
includes the macrophage-inducible C-type lectin (mincle), the
macrophage C-type lectin, dendritic cell C-type lectin (dectin-
2), and the dendritic cell immunoreceptor (DCIR) (Fig. 1,A and
B) (7). Comparison of the sequences of the CRDs of mincle and
BDCA-2 (Fig. 1C) reveals conservation of structural framework
residues including disulfide bonds and the features associated
with the characteristic sugar-binding site in C-type CRDs,
including five amino acids that form the conserved Ca2-bind-
ing site.
TABLE 1
Crystallographic data statistics
Data
BDCA-2 with
-methyl mannoside
BDCA-2 with
Gal1–4GlcNAc1–2Man
Symmetry P22121 P22121
Wavelength (Å) 1.03319 0.97950
Unit cell lengths (Å) a 37.73, b 69.58, c 117.51 a 37.56, b 67.64, c 118.14
Resolution Å (last shell) 28.88–1.65 (1.69–1.65) 37.56–2.90 (3.07–2.90)
Rsyma 5.4 (54.6) 14.6 (47.2)
Mn(I) half-set correlation CC(1/2) 0.999 (0.749) 0.985 (0.823)
Mean (I/(I)) 17.5 (2.5) 8.7 (4.3)
% complete 99.8 (96.5) 99.2 (97.4)
Number of unique reflections 38138 7094
Average multiplicity 6.4 (4.9) 5.3 (5.2)
aRsym 100 hi (Ii(h)I(h)	)/hiIi(h), where Ii(h) observed intensity, andI(h)	mean intensity obtained from multiple measurements.
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Following expression of the CRD from BDCA-2 in E. coli as
inclusion bodies, several protocols for renaturation were
investigated, and attempts were made to purify the CRD on
high density mannose-Sepharose resin, by analogy to protocols
used for mincle and other C-type lectins. When renatured pro-
tein was applied to an extended affinity column in a small sam-
ple volume, retardation of a band corresponding to the CRD
fromBDCA-2 was observed (Fig. 2A). Although the protein did
not stick tightly to the column and washed through in the pres-
ence of Ca2, the results provide evidence that BDCA-2 has at
least weak mannose binding activity.
Based on the previous finding that a galactose-terminated
biantennary glycan is a ligand for BDCA-2 (13), an alternative
affinity resin was created by immobilizing a desialylated prepa-
ration of glycopeptide bearing a biantennary glycan, isolated
from chicken egg yolks. With this oligosaccharide resin, the
expressed CRD of BDCA-2 bound tightly in the presence of
Ca2 and could be eluted with EDTA (Fig. 2B). This approach
provided a rapidmethod for isolation of natively folded protein
and confirmed that BDCA-2 binds to the desialylated oligosac-
charide in a Ca2-dependent manner. In addition to the
untagged CRD, a version in which a biotinylation tag was
attached to the C terminus was also prepared by the same
procedures.
Analysis of Sugar Binding—The biotin tag attached to the C
terminus of the CRD was used to generate tetrameric com-
plexes of CRD with fluorescently labeled streptavidin for
screening of the most recent version of the glycan array at the
Consortium for Functional Glycomics, which has been
expanded to 610 glycans (29). Screening of the expanded array
TABLE 2
Crystallographic refinement statistics
Data
BDCA-2 with
-methyl mannoside
BDCA-2 with
Gal1–4GlcNAc1–2Man
Number of reflections used for refinement 38083 7062
Reflections marked for Rfree 1,905 354
Rfreea 21.4 26.3
Rcrysta 17.3 17.8
B factors (Å2)
Average 26.0 32.1
Protein 24.7 32.1
Ca2 21.6 22.0
Sugars 26.5 31.8
Waters 34.0
Bond length root mean square deviation (Å) 0.011 0.013
Angle root mean square deviation (°) 1.03 1.18
Ramachandran plot: (% in each region)b
(preferred/allowed/outliers)
93.5/5.4/1.1 89.3/8.3/2.4
a R and Rfree 100 hFo(h) Fc(h)/hFo(h), where Fo(h) observed structure factor amplitude, and Fc(h) calculated structure factor amplitude for the working and
test sets, respectively.
b As defined in Coot.
FIGURE 1. Sequence of human BDCA-2. A, summary of the organization of BDCA-2 and other type 2 transmembrane receptors containing C-type CRDs. B,
dendrogram showing the relationships between the CRD portions of this group of C-type lectins. The subgroup containingmincle and BDCA-2 is highlighted
in the violet box. C, sequence of BDCA-2 compared with sequences of cow and human mincle. The N terminus of the CRD is denoted by the arrow. Disulfide
bonds are indicated by blue lines between conserved cysteine residues, which are highlighted in yellow. Amino acid residues that create the conserved
Ca2-binding site are indicated in green, and residues in mincle that create the two accessory Ca2-binding sites in mincle are highlighted in violet and pink.
Residues that form part of the extended sugar-binding site of BDCA-2 are highlighted with orange. The putative transmembrane domains are shown in blue.
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confirmed binding to biantennary glycans with terminal galac-
tose residues, as previously observed with versions of the array
containing 264 and 320 glycans (13), and revealed a number of
additional ligands. However, there were still a limited number
of strong signals (Fig. 3). The 13 highest signals were obtained
for glycans bearing terminal Gal1–4GlcNAc1–2Man or
Gal1–3GlcNAc1–2Man epitopes. All but two of the glycans
containing such epitopes appear in the top 28 signals. However,
the signals are consistently lower when the epitope is displayed
on the 1–3 branch of bi- or triantennary glycans. Glycans bear-
ing just a trisaccharide epitope bind relatively weakly, but these
trisaccharides are displayed on a relatively short two-carbon
linker that may restrict access to the ligand-binding site. These
results suggest that the primary ligands for BDCA-2 are a very
specific subset of galactose-terminated glycans. Three of the
remaining glycan ligands that lack terminal galactose residues
contain terminal GlcNAc1–2Man epitopes on two branches,
whereas seven other glycans that contain one or more copies of
this terminal epitope, without galactose, rank lower on the
array (glycans ranked 48, 49, 65, 100, 110, 305, and 361), sug-
gesting that this epitope binds more weakly. The only glycan
that does not fit into one of these patterns is the 15th ranked
signal. Previous versions of the array had no tri- or tetra-anten-
nary glycans, which is why these ligands were not previously
detected.
Inhibition of binding is observed as a result of the following
modifications of galactose: fucose at the 2 position; NeuAc,
galactose, GlcNAc, or GalNAc at the 3 position; or NeuAc at
the 6 position. In addition, fucose attached to the 3-OH group
of GlcNAc in the Gal1–4GlcNAc1–2Man epitope or to the
4-OH group of the Gal1–3GlcNAc1–2Man epitope also
inhibits binding. As a result, many common blood group anti-
gens, include the ABO oligosaccharides; the Lewis x, y, a, and b
epitopes; the GalGal structure; and poly N-acetyllactosamine
chains do not bind. Addition of sugars at the 4 position of the
galactose residue is tolerated, because a glycan bearing Gal1–
4Gal on two branches is also bound. However, this epitope is
not commonly found in humans or other mammals (30).
Competition binding studies were performed to investigate
the apparent contradiction between preferential binding to
galactose-terminated glycans seen on the glycan array and the
predicted specificity of the primary binding site for mannose-
type ligands. The biotin tag provided an efficient means of
immobilizing the CRD in streptavidin-coated wells for binding
assays. Based on the earlier studies with neoglycoprotein
ligands (31) and the column results demonstrating weak inter-
actions with mannose, 125I-labeled Man-BSA was used as a
reporter ligand so that relatively low affinity interactions with
monosaccharides could be explored by competition. In all
cases, methyl glycosides were used in competition studies to
avoid potentially confounding interactions involving the free
1-OH group (32). Comparison of mannose and galactose as
competing ligands confirmed the affinity chromatography
results, because the KI for mannose was found to be at least
100-fold lower than theKI for galactose (Fig. 4A). As with other
C-type CRDs that bind mannose, sugars that share the equato-
rial arrangement of 3- and 4-OH groups, including glucose and
GlcNAc, as well as L-fucose, also compete for binding.
To eliminate the possibility that there are two separate sugar-
binding sites in the CRD, the competition experiments were
also performed using 125I-labeled human IgG as the reporter
ligand. The glycans attached to the Fc portion of IgG are all of
the complex type, predominantly terminating in galactose (33).
Based on the known glycan composition of IgG and the prefer-
ence for glycans seen on the glycan array, this glycoprotein
would be expected to bind through the site that binds galactose-
terminated glycans. Nevertheless, the binding competition
results revealed the same preference for mannose over galac-
tose as competing ligands, with exactly the same relative bind-
ing specificity for other monosaccharide ligands (Fig. 4B).
These results argue strongly for the presence of a single binding
site, a conclusion supported by the ability of the IgG to compete
for binding of 125I-Man-BSA (Fig. 4C).
One explanation for the glycan array and monosaccharide
competition data would be that in the most common binding
epitope Gal1–4GlcNAc1–2Man, the mannose binds in the
primary binding site, and the galactose occupies an adjacent
secondary binding site. This result would be consistent with the
finding that only complex glycans in which one of the core
mannose residues has exposed 3- and 4-OH groups are ligands
for BDCA-2.
Characterization of a Primary Sugar-binding Site in
BDCA-2—To investigate the nature of the primary sugar-bind-
ing site in BDCA-2, crystallization of the CRDwas attempted in
FIGURE 2. Purification of the CRD from BDCA-2 by affinity chromatography. A, the CRD was renatured from inclusion bodies by dialysis against Ca2-
containing buffer followed by dialysis against water and lyophilization to obtain a concentrated sample that was applied to a 10-ml column of mannose-
Sepharose. After application of the sample, the column was eluted with 150 mM NaCl, 25 mM Tris-Cl, pH 7.8, 25 mM CaCl2. Fractions of 2 ml were collected. B,
following renaturation by dialysis, the CRD was applied directly to a 5-ml column of desialylated egg yolk glycopeptide immobilized on agarose. The column
was rinsedwith 25ml of 150mMNaCl, 25mM Tris-Cl, pH 7.8, 25mMCaCl2, and protein was elutedwith 150mMNaCl, 25mM Tris-Cl, pH 7.8, 2.5mM EDTA in 1-ml
fractions. In both cases, aliquots (15 l) from fractions were analyzed on SDS-polyacrylamide gels that were stained with Coomassie Blue. The expected
molecular weight of the BDCA-2 CRD is 17,100.
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the presence of Ca2 and-methylmannoside to allow binding
of themonosaccharide ligand. Crystals that diffracted to 1.65 Å
were obtained starting from a solution containing 5 mM CaCl2
and 50 mM -methyl mannoside. The structure was solved by
molecular replacement, using a search model consisting of the
CRD from cow mincle (Protein Data Bank entry 4ZRV), with
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sugar ligand removed (Fig. 5A). There are two copies of the
molecule in the asymmetric unit. The overall fold of the main
portion of the CRD is similar tomincle and other C-type CRDs,
with the N-terminal extension forming an additional pair of 
strands linked by a disulfide bond. The electron density maps
indicated the presence of only one Ca2 per monomer, bound
by the five conserved residues noted in Fig. 1C, to create the
primary sugar-binding site (Fig. 5, B and C). -Methyl manno-
side is bound to this Ca2 in both copies. In copy A, sugar is
bound in two alternate orientations, with roughly the same
occupancies, related by a 180° rotation that interchanges the
positions of the 3- and 4-OH groups. These hydroxyl groups
FIGURE 3. Glycan array analysis of ligand binding to BDCA-2. A complex of biotin-tagged CRD from BDCA-2 with Alexa 488-labeled streptavidin was
used to screen synthetic glycan array version 5.1 at the Consortium for Functional Glycomics at a concentration of 100 g/ml. A, results are arranged in
rank order based on decreasing signal. B, structures corresponding to the 28 top-ranked glycans, plus three additional glycans with potential binding
epitopes, are shown in symbol representation, in which the linkages from NeuAc are 2 and all other linkages are 1. The mannose 1–3 and 1–6
branch point linkages indicated with 3 and 6. Bars in A are color-coded based on the presence of the shaded binding epitopes in B: blue for uncapped
GlcNAc1–2Man, yellow and green for Gal1–4GlcNAc1–2Man on the 1–3 and 1–6 arms, respectively, and pink for Gal1–3GlcNAc1–2Man. After
glycan 28, with a signal of 171, the signal drops to 109 for glycan 29, and the average signal for the remaining glycans is 17. Complete glycan array results
are provided in supplemental Table S1.
FIGURE 4. Competition results to define primary sugar-binding site in BDCA-2. Binding was performedwith biotin-tagged CRD from BDCA-2 bound
to streptavidin-coated wells. A and B, binding of 125I-Man-BSA or 125I-IgG was measured in the presence of competing -methyl glycosides. C, binding
of 125I-Man-BSA was measured in the presence of competing IgG. Half-maximal inhibition values (KI) were obtained by nonlinear least squares fitting
of the data. The values of KI relative to the KI for -methyl mannoside in bar graphs represent the means 
 standard deviations for two to four
independent assays.
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interact with the Ca2 and its amino acid ligands by the net-
work of coordination and hydrogen bonds that are characteris-
tic of C-type CRDs (32).
Although the search model contained three Ca2, a striking
difference between the crystal structure of BDCA-2 and the
structure of mincle is the absence of the two accessory Ca2-
binding sites (Fig. 5D), one near the conserved site and one on
the other side of the CRD, in BDCA-2. Notably, several of the
acidic amino acid side chains that interact with these two addi-
tional Ca2 in mincle have been substituted by basic amino
acids (Fig. 1C). In the structure, the side chains of two of these
basic residues interact directly with the remaining acidic amino
acid side chains (Fig. 5, E and F). Measurement of the effect of
Ca2 concentration on 125I-Man-BSAbinding to BDCA-2 con-
firmed that binding is Ca2-dependent, but rather than being
second order with respect to Ca2 as was found formincle (22),
the binding is best fitted by first order dependence, consistent
with the presence of the single Ca2 site observed in the crystal
structure (Fig. 6A).
Gel filtration analysis of the CRD confirmed that, at physio-
logical pH, the protein is predominantly a monomer (Fig. 6B).
Previously reported structures of a fragment of BDCA-2
revealed a substantially different arrangement of the CRD, in
which a dimer is formed by a domain swap between loops in the
region that is found to contain the Ca2-binding site in the
structure reported here (14). Because those crystals were
obtained in the absence of Ca2, it was suggested that they
represent an alternative, inactive form of the protein thatmight
form under some conditions. The current results support the
interpretation that the previous structures do not represent the
ligand-binding conformation of BDCA-2.
Binding of BDCA-2 to Oligosaccharide Ligands—Quantita-
tive information on the roles of additional sugars beyond man-
nose in the binding of complex N-linked glycans to BDCA-2
was obtained using the binding competition assay. Natural
biantennary ligands were prepared by release of the oligosac-
charide portion of the egg yolk glycopeptidewith proteinN-gly-
cosidase and partial desialylation by mild acid treatment. Ion
exchange chromatography was used to separate the starting
disialylated oligosaccharide frommonosialylated forms and the
fully desialylated forms. Competition assays revealed a nearly
1000-fold increase in affinity upon removal of the two sialic acid
residues (Fig. 7A), confirming that the CRD is selective for
desialylated structures. The apparent affinity for the asialo
biantennary glycan is nearly 20,000-fold higher than the affinity
for mannose, reflecting the importance of additional sugars in
the binding interaction.
The role of individual sugars was further dissected with syn-
thetic di- and trisaccharides corresponding to parts of the
Gal1–4GlcNAc1–2Man epitope identified in the glycan
FIGURE 5. Structural analysis of the primary sugar-binding site in BDCA-2. A, overall structure of BDCA-2 with bound -methyl mannoside. B, Ca2 and
-methyl mannoside in the primary site of BDCA-2 monomer B. C, -methyl mannoside in the primary site of monomer A. Fo Fc map at 2.5  showing two
conformations of the sugar related by a 180° rotation that switches the positions of O3 and O4. The occupancies of the conformations indicated in dark
blue:light blue are 0.54:0.46, with the dark blue conformation corresponding to what is seen in monomer B. D, structure of the CRD from cowmincle (Protein
Data Bank entry 4ZRV), with trehalose bound at the conserved Ca2 and two accessory Ca2 highlighted. This structure (H. Feinberg, S. A. F. Jégouzo, M. E.
Taylor, K.Drickamer, andW. I.Weis, unpublishedobservations),whichwasusedas the searchmodel for themolecular replacement solution, is similar toProtein
Data Bank entry 4KZV, butwith a third Ca2 replacing the boundNa, in a position analogous to that seen inmannose-binding protein and other C-type CRDs
(4). E and F, arrangement of amino acid residues in BDCA-2 in the positions at which two accessory Ca2 are bound to the CRD of mincle. Ca2 is shown in
orange, oxygen atoms in red, nitrogen atoms are dark blue, and carbon atoms of the sugars are yellow.
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array analysis. The addition of GlcNAc to mannose increases
the affinity by 100-fold, whereas addition of galactose increases
the affinity by a further 10-fold (Fig. 7B). These results are con-
sistent with the finding on the glycan array, which showed
binding of BDCA-2 to glycans bearing two terminal
GlcNAc1–2Man structures, whereas those with a single
GlcNAc1–2Man terminus did not bind significantly above
background. On the other hand, the presence of a single termi-
nal Gal1–4GlcNAc1–2Man structure is sufficient for strong
binding. These results indicate that interactions with both
GlcNAc and galactose probably contribute to the strong affinity
of the galactose-terminated complex N-linked glycans.
To investigate the arrangement of an oligosaccharide in the
binding site of the CRD from BDCA-2, crystals were prepared
in the presence of the trisaccharide ligand. The structure
reveals that, as proposed, the mannose residue is located in the
primary binding site, in the more common orientation seen in
the crystals with -methyl mannoside (Fig. 8). The other two
sugar residues occupy a shallow groove, the width of which
accommodates the 1–4-linked sugar but that could potentially
hold an even larger oligosaccharide adjacent to the primary
binding site. The temperature factors for the ligand are not
significantly different from those for the protein (Table 2), indi-
cating that the oligosaccharide is fully occupied in the struc-
ture, and the electron density (Fig. 8C) unambiguously defines
the bound oligosaccharide orientation and conformation. On
one side of the GlcNAc, the carbonyl group in the acetamido
substituent at position 2 is engaged in hydrogen bonds with the
side chains of Asn-184, Arg-186, and Asn-194. This last side
chain is also a Ca2 ligand and part of the primary binding site
(Fig. 8A). On the other side of the GlcNAc, residues Val-200
and Ile-196 make van der Waals contacts with the exocyclic
6-hydroxymethyl group (Fig. 8B). For the galactose, the side
chain of Ser-139 is hydrogen-bonded to OH-6, and the side
chain of Gln-202 forms hydrogen bonds with OH-2 and makes
van der Waals contact with C3 (Fig. 8, A and B).
FIGURE 6. Ca2 dependence and gel filtration analysis of the CRD from BDCA-2. A, Ca2 dependence of 125I-Man-BSA binding to BDCA-2. Binding of
125I-mannose-BSA to the biotin-tagged CRDs immobilized in streptavidin-coated wells was quantified. After binding of ligand in 150 mM NaCl and 25 mM
Tris-Cl, pH7.8, in thepresenceof various concentrationsofCa2, wellswerewashedwithbuffer containing150mMNaCl, 25mMTris-Cl, pH7.8, and25mMCaCl2.
The experimental data, shown as black circles, were fitted to first and second order binding equations, shown respectively as blue and green lines, using a
nonlinear least squares fitting program. B, gel filtration analysis of the CRD fromBDCA-2 on a 7.5 300-mmcolumnof Sephacryl S75 elutedwith 100mMNaCl,
10 mM Tris-Cl, pH 7.8, and 2.5 mM EDTA at a flow rate of 0.5 ml/min. Blue trace is with protein, and green trace is a mock sample without protein, showing that
the peak eluting at 17 ml results from the presence of Ca2-EDTA complex in the sample. Positions of molecular weight standards are shown at the top.
FIGURE 7.Quantification of oligosaccharide binding to BDCA-2. Binding competition assays were conductedwith biotin-tagged CRD from BDCA-2 immo-
bilizedon streptavidin-coatedplates, using 125I-Man-BSAas reporter ligand.A, competitionwithbiantennary glycans released fromeggyolk glycopeptide and
treatedwithmild acid to remove sialic acid residues. B, competitionwith synthetic di- and trisaccharides. Glycan structures are encoded as in Fig. 3. The values
of KI are presented as means
 standard deviations for two to four independent assays.
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The importance of the interactions observed in the crystal
structure was confirmed by mutating residues that make con-
tacts with the GlcNAc and galactose residues in the extended
binding site. In the GlcNAc site, changing Val-200 or Arg-186
to alanine results in reductions of 3- and 10-fold in the affinities
for both di- and trisaccharide ligands GlcNAc1–2Man and
Gal1–4GlcNAc1–2Man, whereas the mutation N184A
almost completely abolishes enhanced binding to both ligands
(Fig. 9). The first two of these mutations preserve the preferen-
tial binding of the trisaccharide ligand compared with the
disaccharide ligand, which is consistent with the fact that the
galactose-binding portion of the site has not been changed.
Because of the very large reduction in overall binding affinity
for the N184A mutation, it was not possible to test the trisac-
charide ligand at sufficiently high concentration to confirm
whether it still binds better than the disaccharide.
Mutation of residues that interact with the galactose would
be expected to affect binding of the Gal1–4GlcNAc1–2Man
trisaccharide more than the disaccharide lacking galactose. In
line with this prediction, mutation of either Ser-139 or Gln-202
to alanine results in a significant loss of relative affinity for the
trisaccharide compared with the disaccharide (Fig. 9).
Although Ser-139 in monomer A is close enough to the 3-OH
group of GlcNAc to make a hydrogen bond, in monomer B, it
interacts only with the galactose residue. The fact that the
S139A mutation has little effect on binding of the disccharide
ligand suggests that the potential hydrogen bond to GlcNAc
does not contribute significantly to binding of the disaccharide.
The finding that the Q202A mutation results in a decrease in
affinity for the disaccharide compared with mannose suggests
that when the disaccharide lacking galactose is bound, GlcNAc
may shift slightly to interact with Gln-202 rather than Ser-139.
In any case, the characteristics of themutant CRDs support the
conclusion that the arrangement of the trisaccharide observed
in the crystal structure accurately reflects the mode of interac-
tion between the CRD and the ligand in solution.
The arrangement of the binding site is consistent with the
range of ligands on the glycan array that bind BDCA-2. For
example, the broad canyon adjacent to the primary binding site
would accommodate galactose linked 1–3 to the GlcNAc resi-
due, as well as the 1–4-linked galactose observed in the crystal
structure (Fig. 8D). The 4-OH group of the 1–4-linked galac-
tose projects away from the surface of the protein, which
explains why addition of a further galactose at this position is
tolerated. In contrast, addition of sugars to the 2-, 3-, or 6-OH
groups would result in steric clashes. For example, overlaying
the NeuAc2–3Gal1–4GlcNAc and NeuAc2–6Gal1-
4GlcNAc portions of various glycans observed in crystal struc-
tures of glycoproteins indicates that all of the observed confor-
mations of the sialic acid residues would clash with the protein
surface. Similarly, the 3-OH group of GlcNAc points toward
the protein surface, so addition of fucose at this position would
also result in a steric clash.
Ligands with the Gal1–4GlcNAc1–2Man epitope on the
1–3 arm of bi-, tri-, and tetra-antennary glycans bind better
FIGURE 8. Structural analysis of extendedbinding site in BDCA-2.A and B,
BDCA-2 complex with Gal1–4GlcNAc1–2Man showing interactions
between the protein and the GlcNAc and Gal moieties of the elongated car-
bohydrate. C, Fo Fcmap at 3.0 (green), showingGal1–4GlcNAc1–2Man
at the binding site. D, surface representation of BDCA-2 with bound
Gal1–4GlcNAc1–2Man depicted as sticks with yellow carbon atoms. A
galactose residue in 1–3 linkage to the GlcNAc, shown with gray carbon
atoms, has beenmodeled to show that it can be accommodated in the bind-
ing site. Ca2 is shown in orange, oxygen atoms are red, and nitrogen atoms
are blue.
FIGURE 9.Mutational analysis of extended binding site in BDCA-2. Affin-
ities for disaccharide and trisaccharide ligands are compared for thewild type
and mutant CRDs, by plotting ratios of inhibition constants for oligosaccha-
rides and-methylmannoside in the solid phase binding assay. The values of
means
 standard deviations for two to four assays are shown. For the two
measurementsmarkedwith an asterisk, no inhibitionwas seen at the highest
trisaccharide concentration that could be tested (200 M), so the error bars
represent the highest possible ratio of affinities, based on an estimated KI
value	 500 M.
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than those in which the epitope is present on the 1–6 arm.
Modeling with the glycan from IgG (Protein Data Bank entry
1HZH) and other biantennary glycans reveals that in all cases,
the Gal1–4GlcNAc1–2Man epitope on the 1–3 arm can be
accommodated in the binding site of BDCA-2, with both the
1–6 arm and the chitobiose core projecting away from the pro-
tein. In contrast, for most of the available structures, there is a
clash between the protein surface and the chitobiose core of the
oligosaccharide when the trisaccharide binding epitope on the
1–6 arm is positioned in the binding site, although in one case
in which the 1–6 arm assumes an alternative conformation
(Protein Data Bank entry 1SLA), the terminal trisaccharide on
this arm can bind. Thus, the less favorable interaction with the
1–6 branch probably results from the need for the oligosaccha-
ride to assume a less favored orientation in order for this bind-
ing to occur. Particularly weak binding is observed for glycans
that are branched on the 1–3 arm, including tetra-antennary
glycans, because these structures contain linkages to the 4 posi-
tion of themannose on this branch, which blocks binding to the
favored terminal structure.
Discussion
The results of the analysis reported here confirm and extend
earlier reports that BDCA-2 binds to galactose-terminated
biantennary glycans, by defining an epitope found on a limited
number of bi- and triantennary glycans that are not fully sialy-
lated. The results also reconcile an apparent discrepancy
between the nature of these ligands and the predicted speci-
ficity of the primary binding site for mannose-type ligands,
because the specificity for galactose-terminated glycans comes
from secondary site interactions rather than binding to the
Ca2 in the primary binding site.
These findings help to put previously described structures of
BDCA-2 in perspective. In these structures, formed under low
Ca2 conditions, pairs ofCRDsundergo domain swapping (14).
As was noted, these structures are unlikely to be the ligand-
binding conformation at the cell surface because of the absence
of bound Ca2, but they may represent forms that would occur
under some conditions. A similar domain-swapped structure
has been observed for another sugar-binding C-type CRD,
domain 4 of themannose receptor (34), and a domain-swapped
dimer with somewhat different geometry has been found for
snake venom IX/X-binding protein, which contains a C-type
lectin-like domain that does not bind sugars (35). The finding
that only a single Ca2 binds to the CRD from BDCA-2 may
mean that it is more susceptible to such a reorganization.
The arrangement of galactose-terminated glycans in the
binding site of BDCA-2 contrasts with the arrangement of the
asialoglycoprotein receptor, which can bind some of the same
glycans, but in which the primary binding is through the galac-
tose residue (36, 37). A similar situation is observed for binding
of Lewisx to DC-SIGN and the scavenger receptor C-type lec-
tin, with the former binding through fucose in the primary
binding site and galactose in an adjacent secondary site,
whereas the latter binds with galactose in the primary binding
site and fucose making secondary interactions (5, 38).
It is interesting to compare the structure of human BDCA-2
with the structure of the mouse DCIR2, which binds to bian-
tennary N-linked glycans with bisecting GlcNAc residues
attached to the 4-OH group of the core mannose residue (39).
Superficially, these specificities seem very different, but the
binding epitope for DCIR2 includes the GlcNAc1–2Man that
binds to BDCA-2, and a similar arrangement of these two resi-
dues is seen in the two proteins (Fig. 10). Similarities are seen
both in the position of mannose in the primary binding site and
the contacts made with GlcNAc in the secondary binding site.
In addition to these interactions, specificity for the bisecting
GlcNAc is achieved inDCIR2 by interaction of this residuewith
Glu-202 and Asp-223, which correspond to Glu-178 and Val-
200 in BDCA-2. The absence of the aspartic acid residue in
BDCA-2 would lead to destabilization of this binding
interaction.
Defining the types of ligands that bind to BDCA-2 provides
some insights into potential biological functions of the recep-
tor. For example, the structure explains why BDCA-2 does not
bind to glycans bearing terminal sialic acid residues, because
addition of NeuAc at either the 3- or 6-OH group of galactose
results in steric clashes. This arrangement contrasts with the
asialoglycoprotein receptor, in which the 3-OH of galactose is
buried in the primary binding site so that ligands with 2–3
linked sialic acid are excluded, whereas the 6-OH group is
exposed, so that sialylation is tolerated on this position (36, 37).
The preference for desialylated glycans might seem at odds
with the rapid clearance of glycoproteins bearing such glycans
by the hepatic asialoglycoprotein receptor. However, there are
notable examples of proteins, including serum IgG, that largely
lack terminal sialic acid. As demonstrated here, this unusual
glycosylation allows binding of IgG to BDCA-2 with an affinity
of 1 M. Because the glycans on IgG are located on the con-
stant Fc domain, BDCA-2 could function as a previously unrec-
ognized Fc receptor with an affinity similar to that observed for
FcRII and FcRIII (40). Cross-linking of BDCA-2 has been
demonstrated to block signaling initiated in response to Toll-
like receptors in plasmacytoid dendritic cells, resulting in
decreased type 1 interferon secretion (6). Interferonproduction
FIGURE 10. Comparison of ligand binding sites in human BDCA-2 and
mouseDCIR2. The structure ofmouseDCIR2 is taken fromProtein Data Bank
entry 3VYK and is shown in gray. BDCA-2 is shown in cyan. In the superposed
structures, carbon atoms of Gal1–4GlcNAc1–2Man bound to BDCA-2 are
in yellow, and carbon atoms of the biantennary glycanwith bisectingGlcNAc,
bound to DCIR2, are in gray. Ca2 is shown in orange, oxygen atoms in red,
and nitrogen atoms are dark blue.
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is important in stimulating the normal immune response, and
high levels can lead to autoimmunity (41). Thus, the finding
that serum IgG is a ligand for BDCA-2 suggests a potential
regulatorymechanism in response to rising levels of serum IgG,
which would tend to dampen down the response once IgG has
reached sufficient concentration in the blood. Because BDCA-2
is expressed in humans but not in mice, the consequences of
BDCA-2binding to IgGor other serumglycoproteins cannot be
assessedwithmousemodels, and its propertiesmay account for
some differences in the behavior of the human and mouse
immune systems.
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